Sign in
Active, not recruitingPhase 2

RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Key facts

Who runs it
Altimmune, Inc.
Where
Atlanta, Bastrop, Bradenton, Brownsville, Dallas, Doral, Edinburg, Fort Myers, Fresno, Houston, Indianapolis, La Jolla, Las Vegas, Louisville, Manhasset, Marrero, Miami, Miami Lakes, Naples, New York, North Little Rock, Orlando, Pasadena, Peoria, San Antonio, Seattle, St Louis, Syracuse, Tucson, Waco, West Monroe, Westlake, and Wilmington, United StatesSee the 33 sitesAlso in 1 other country, 1 site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
121 people enrolled
Started
16 Jun 2025
Expected to end
30 Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pemvidutide
  • Placebo
Record updated
17 August 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Male or female ages 18 to 75 years, inclusive
  • Overweight or obesity, defined as BMI ≥ 25 kg/m2
  • History of alcohol misuse for the prior 3 years, with an alcohol intake ≥ 50 grams per day for males and ≥ 40 grams per day for females on average in the past year
  • Evidence of recent alcohol use, defined as PEth level ≥ 35 ng/mL at screening
  • Liver stiffness of 10.0-24.9 kPa by VCTE, inclusive

Who cannot take part

  • Presence of clinically significant alcohol withdrawal symptoms, defined as CIWA-Ar score ≥ 10 at screening and/or prior to randomization
  • History and/or current diagnosis of schizophrenia, bipolar disorder, psychotic disorder, or another severe psychiatric disorder, unless documented as well-controlled by the Investigator for at least 6 months prior to screening and cleared by the Medical Monitor
  • History of hospitalization for alcohol withdrawal within the past year
  • History of seizures related to alcohol within the past year
  • Attempted suicide and/or serious suicidal intention or plan in the past 10 years

Where in United States

Also in 1 other country, 1 site

  • Atlanta, GeorgiaHospital not named in the registry
  • Bastrop, LouisianaHospital not named in the registry
  • Bradenton, FloridaHospital not named in the registry
  • Brownsville, TexasHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Doral, FloridaHospital not named in the registry
  • Edinburg, TexasHospital not named in the registry
  • Fort Myers, FloridaHospital not named in the registry
  • Fresno, CaliforniaHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • La Jolla, CaliforniaHospital not named in the registry
  • Las Vegas, NevadaHospital not named in the registry
  • Louisville, KentuckyHospital not named in the registry
  • Manhasset, New YorkHospital not named in the registry
  • Marrero, LouisianaHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Miami Lakes, FloridaHospital not named in the registry
  • Naples, FloridaHospital not named in the registry
  • New YorkHospital not named in the registry
  • North Little Rock, ArkansasHospital not named in the registry
  • Orlando, FloridaHospital not named in the registry
  • Pasadena, CaliforniaHospital not named in the registry
  • Peoria, ArizonaHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • Seattle, WashingtonHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • Syracuse, New YorkHospital not named in the registry
  • Tucson, ArizonaHospital not named in the registry
  • Waco, TexasHospital not named in the registry
  • West Monroe, LouisianaHospital not named in the registry
  • Westlake, OhioHospital not named in the registry
  • Wilmington, North CarolinaHospital not named in the registry

About the trial

What the trial wants to find out

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.

The 2 groups in the trial

  • Pemvidutide 2.4 mgExisting treatment, for comparison

    Treatment: Pemvidutide

  • PlaceboPlacebo, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Record updated
17 August 2026